The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies

被引:82
作者
O'Toole, Dermot
Saveanu, Alexandru
Couvelard, Anne
Gunz, Ginette
Enjalbert, Alain
Jaquet, Philippe
Ruszniewski, Philippe
Barlier, Anne [1 ]
机构
[1] Univ Mediterranee, Lab Interact Cellulaires Neuroendocriniennes, CNRS, UMR6544,Inst Fed Jean Roche,Fac Med Nord, Marseille, France
[2] Hop Beaujon, Serv Gastroenterol Pancreatol, Pole Malad Appareil Digest, Clichy, France
[3] Hop Beaujon, Serv Anatomopathol, Clichy, France
[4] Ctr Hosp Univ Concept, Biochem & Mol Biol Lab, Marseille, France
关键词
D O I
10.1530/eje.1.02307
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Somatostatin (sst) are present in the majority of gastro-entero-pancreatic (GEP) tumours. Effects of somatostatin receptor (sst) analogues are partial and of limited duration. Cell lines derived from GEP express dopaminergic receptors D-2. New chimeric analogues simultaneously recognising sst, and sst(5) or sst(2) and D-2 have additive effects in inhibition of GH and prolactin secretion in pituitary adenomas. Our aim was to quantify the expression of sst and D2 mRNA in human GEP tumours. Design and methods: mRNA expression of sst(1). sst(2), sst(3) and sst(5) as well as D-2, was analysed using real-time PCR (TaqMan probe) in a series of 3 5 patients with GEP tumours (pancreas (n = 19) and intestinal (n = 16)). Levels of expression were compared with a group of 13 somatotroph adenomas. Results: All GEP tumours express sst(1), sst(2) and D-2. Expression of sst(3) and sst(5) was observed in 89 and 76% of tumours respectively with highly variable levels. sst(2) mRNA expression was higher in nonfunctional tumours (P < 0.009) and sst5 was higher in pancreatic than in intestinal tumours (P < 0.02). Whereas sst(2) levels were similar between GEP and somatotroph tumours, levels of sst5 and D, were higher in the former (394.9 +/- 156.1X10(-2) vs 69.7 +/- 19.5X10(-2) copy/copy beta-Gus (P < 0.0036) and 519.6 +/- 121.2X10(-2) vs 50.0 +/- 21.6X10(-2) copy/copy beta-Gus (P < 0.0001) respectively). In small tumours (< 30mm), sst(2) density appeared as a crucial parameter in somatostatin receptor scintigraphy results, whereas in big tumours, a consistent bias in SRS results was introduced by the size. In pancreatic GEP, high-level sst(3) expression was found in tumours with more active angiogenesis (higher microvessel density and vascular endothelial growth factor expression (P < 0.03)). Conclusions: GEP tumours co-express sst(2) and D-2 in 100% of cases and sst(5) in 89% thus supporting the testing of bi-specific agonists (sst(2)/sst(5) or sst(2)/D-2) in these tumours.
引用
收藏
页码:849 / 857
页数:9
相关论文
共 48 条
[1]   Inhibition of endothelial proliferation by the somatostatin analogue SOM230 [J].
Adams, RL ;
Adams, IP ;
Lindow, SW ;
Atkin, SL .
CLINICAL ENDOCRINOLOGY, 2004, 61 (04) :431-436
[2]   Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis [J].
Albini, A ;
Florio, T ;
Giunciuglio, D ;
Masiello, L ;
Carlone, S ;
Corsaro, A ;
Thellung, S ;
Cai, T ;
Noonan, DM ;
Schettini, G .
FASEB JOURNAL, 1999, 13 (06) :647-655
[3]   Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity [J].
Arena, S ;
Barbieri, F ;
Thellung, S ;
Pirani, P ;
Corsaro, A ;
Villa, V ;
Dadati, P ;
Dorcaratto, A ;
Lapertosa, G ;
Ravetti, JL ;
Spaziante, R ;
Schettini, G ;
Florio, T .
JOURNAL OF NEURO-ONCOLOGY, 2004, 66 (1-2) :155-166
[4]   Impact of gsp oncogene on the expression of genes coding for Gsα, Pit-1, Gi2α, and somatostatin receptor 2 in human somatotroph adenomas:: Involvement in octreotide sensitivity [J].
Barlier, A ;
Pellegrini-Bouiller, I ;
Gunz, G ;
Zamora, AJ ;
Jaquet, P ;
Enjalbert, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (08) :2759-2765
[5]   Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression [J].
Couvelard, A ;
O'Toole, D ;
Turley, H ;
Leek, R ;
Sauvanet, A ;
Degott, C ;
Ruszniewski, P ;
Belghiti, J ;
Harris, AL ;
Gatter, K ;
Pezzella, F .
BRITISH JOURNAL OF CANCER, 2005, 92 (01) :94-101
[6]   Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas [J].
de Sá, SV ;
Corrêa-Giannella, ML ;
Machado, MC ;
de Souza, JJS ;
Pereira, MAA ;
Patzina, RA ;
Siqueira, SAC ;
Machado, MCC ;
Giannella-Neto, D .
ENDOCRINE-RELATED CANCER, 2006, 13 (01) :69-78
[7]   Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation [J].
Ferone, D ;
Arvigo, M ;
Semino, C ;
Jaquet, P ;
Saveanu, A ;
Taylor, JE ;
Moreau, JP ;
Culler, MD ;
Albertelli, M ;
Minuto, F ;
Barreca, A .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2005, 289 (06) :E1044-E1050
[8]   Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities [J].
Florio, T ;
Morini, M ;
Villa, V ;
Arena, S ;
Corsaro, A ;
Thellung, S ;
Culler, MD ;
Pfeffer, U ;
Noonan, DM ;
Schettini, G ;
Albini, A .
ENDOCRINOLOGY, 2003, 144 (04) :1574-1584
[9]  
Hall GH, 2005, INT J ONCOL, V27, P1283
[10]   The pathophysiological consequences of somatostatin receptor internalization and resistance [J].
Hofland, LJ ;
Lamberts, SWJ .
ENDOCRINE REVIEWS, 2003, 24 (01) :28-47